41LOW

IVX

INVION FPO [IVX]
Invion Limited, a clinical-stage life sciences company, researches and develops Photosoft technology for the treatment of cancers, atherosclerosis, and infectious diseases in Australia. The company develops IVX-PDT, a photosensitising agent to treat a range of cancers, such as skin, prostate, ano-genital, glioblastoma multiforme, lung, and ovarian cancers; and human papilloma virus. It is also involved in the development of INV043, which is in Phase II clinical trial for the treatment of patients with prostate cancer; and in Phase I/II clinical trial to treat non-melanoma skin cancer, as well as for the treatment of oesophageal cancer. The company has collaborations with Hudson Institute of Medical Research, Peter MacCallum Cancer Centre, Dr. I&B Co., Ltd., and Hanlim Pharm Co., Ltd. Invion Limited was incorporated in 2000 and is headquartered in Melbourne, Australia.
Healthcare · ASX Small Cap
$0.0750 +0.0%

Updated 26 Mar 2026 · Scores refresh every scan

Score Breakdown

Technical57
Catalyst53
Sentiment50
Fundamental17
Momentum54
Risk Gate45
Get alerts when IVX's score changes
Free watchlist with daily scans for 2,200+ ASX stocks
Track IVX — Free

Active Signals

Bullish Signals

  • RSI drifting toward oversold territory — worth watching
  • Stochastic is deep in oversold territory — bounce conditions forming
  • Sitting near support — this level has held before and could attract buyers again
  • Critical cash runway (0.2 quarters)
  • Pre-revenue with limited cash
  • Near 52-week low (0% of range)
  • Micro-cap ($5-20M) - high risk
  • Capital raise activity (5 events)
  • Dilution velocity warning (5 raises recently)
  • Sentiment is mixed — no strong consensus either way
  • The bigger volume days are the up days — volume-weighted momentum is positive (1.86%/day)
  • Pre-revenue company — Altman Z-Score not applicable
  • Elevated dilution risk (5 recent capital raises)
  • RBA hiking (-3pts)

Risk Signals

  • Trading below both moving averages — the trend is working against this one
  • Below the 200-day average — the long-term trend is still working against it
  • Piotroski F-Score weak (2/9, low-confidence approx)
  • Not enough chatter to gauge sentiment — defaulting to neutral
  • Overseas neutral (-2pts, S&P500 neutral, VIX 25)
Ask Scout AI about IVX
"What's driving IVX's score?" "How does IVX compare to peers?" "Key risks for IVX?"
3 free messages/day · Unlimited with Pro

Recent Catalysts

NONE Proposed issue of securities - IVX
NONE Proposed issue of securities - IVX
NONE Proposed issue of securities - IVX
Announcement tone +3pts

Recent ASX Announcements

2026-03-23 Proposed issue of securities - IVX
2026-03-23 Proposed issue of securities - IVX
2026-03-23 Proposed issue of securities - IVX
2026-03-23 Proposed issue of securities - IVX
2026-03-18 Proposed issue of securities - IVX

Key Metrics

$7.3M
Market Cap
76K
Avg Volume
2.0x
Vol Ratio
$0.07 — $0.20
52-Week Range
N/A
Short Interest
N/A
Cash Runway
-111.5%
ROE
N/A
Profit Margin

CANSLIM Analysis

FactorRatingDetail
CCurrent EPSfailEPS Growth: 0%
AAnnual EarningsfailCAGR: 0%
NNew Highs / Catalystsneutral
SSupply & DemandneutralFloat: 58%
LLeader vs LaggardlaggardRS: -1
IInstitutional Sponsorshipinsufficient_dataInst: 0%
MMarket DirectionneutralNeutral

Sector: Healthcare

Ranked #86 of 117 · Sector avg: 46

View all Healthcare signals →
Related Tickers
ATX 59PNV 56IMM 55EYE 55AHC 55
Compare:IVX vs ATXIVX vs PNVIVX vs IMM
Scout Pro — Deeper Analysis for IVX
Try Pro free for 30 days
Share this analysis

Track IVX and 2,200+ ASX stocks

Get free access to Scout's AI-powered dashboard with daily scans, watchlist alerts, and conviction scoring for every ASX small cap.

Open Dashboard — Free Free Screener
No credit card required